Azmon A[au] - Search Results

Year	Number of Results
2013	1
2014	1
2016	1
2017	1
2018	1
2019	1
2020	2
2021	1
2022	1
2024	0

1

The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis.

Derfuss T, Sastre-Garriga J, Montalban X, Rodegher M, Wuerfel J, Gaetano L, Tomic D, Azmon A, Wolf C, Kappos L. Derfuss T, et al. Among authors: azmon a. Mult Scler J Exp Transl Clin. 2020 Mar 30;6(1):2055217320907951. doi: 10.1177/2055217320907951. eCollection 2020 Jan-Mar. Mult Scler J Exp Transl Clin. 2020. PMID: 32284874 Free PMC article.

2

On the estimation of the reproduction number based on misreported epidemic data.

Azmon A, Faes C, Hens N. Azmon A, et al. Stat Med. 2014 Mar 30;33(7):1176-92. doi: 10.1002/sim.6015. Epub 2013 Oct 10. Stat Med. 2014. PMID: 24122943

3

Structural differences in mixing behavior informing the role of asymptomatic infection and testing symptom heritability.

Santermans E, Van Kerckhove K, Azmon A, John Edmunds W, Beutels P, Faes C, Hens N. Santermans E, et al. Among authors: azmon a. Math Biosci. 2017 Mar;285:43-54. doi: 10.1016/j.mbs.2016.12.004. Epub 2016 Dec 24. Math Biosci. 2017. PMID: 28027885

4

Effect of fingolimod on health-related quality of life in paediatric patients with multiple sclerosis: results from the phase 3 PARADIGMS Study.

Krupp L, Banwell B, Chitnis T, Deiva K, Gaertner J, Ghezzi A, Huppke P, Waubant E, DeLasHeras V, Azmon A, Karan R. Krupp L, et al. Among authors: azmon a. BMJ Neurol Open. 2022 Feb 24;4(1):e000215. doi: 10.1136/bmjno-2021-000215. eCollection 2022. BMJ Neurol Open. 2022. PMID: 35308898 Free PMC article.

5

International sentinel site surveillance of patients with transfusional hemosiderosis treated with deferasirox in actual practice setting.

El-Beshlawy A, Inusa B, Beneitez Pastor D, Xicoy B, Soledada Duran Nieto M, Bruederle A, Azmon A, Gilotti G, Elalfy M. El-Beshlawy A, et al. Among authors: azmon a. Hematology. 2019 Dec;24(1):238-246. doi: 10.1080/16078454.2018.1558758. Hematology. 2019. PMID: 30558524 Free article. Clinical Trial.

6

Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study.

Chitnis T, Banwell B, Krupp L, Arnold DL, Bar-Or A, Brück W, Giovannoni G, Greenberg B, Ghezzi A, Waubant E, Rostasy K, Deiva K, Huppke P, Wolinsky JS, Zhang Y, Azmon A, K-Laflamme A, Karan R, Gärtner J. Chitnis T, et al. Among authors: azmon a. Mult Scler. 2021 May;27(6):922-932. doi: 10.1177/1352458520936934. Epub 2020 Jul 7. Mult Scler. 2021. PMID: 32633694

7

Effect of deferasirox + erythropoietin vs erythropoietin on erythroid response in Low/Int-1-risk MDS patients: Results of the phase II KALLISTO trial.

Gattermann N, Coll R, Jacobasch L, Allameddine A, Azmon A, DeBonnett L, Bruederle A, Jin J; KALLISTO study investigators. Gattermann N, et al. Among authors: azmon a. Eur J Haematol. 2018 May 19. doi: 10.1111/ejh.13096. Online ahead of print. Eur J Haematol. 2018. PMID: 29777631

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

7 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year